Hematology

Audio Journal of Oncology SAN DIEGO—The first-line treatment of choice for older patients with chronic lymphocytic leukemia (CLL) should now be single agent ibrutinib according to conclu

SAN DIEGO—Patients 70 years old and younger with previously untreated chronic lymphocytic leukemia (CLL) lived longer and had progression of their disease delayed when treated with ibrutinib (an irrev

NEW ORLEANS—A new oral tyrosine kinase inhibitor drug — idelalisib — has proved effective — and to have low toxicity — in patients with chronic lymphocytic leukaemia (CLL). Richard Furman MD from Weil

The rare, fatal lympho-proliferative condition: Multicentric Castleman’s Disease — MCD — could soon be treatable following findings announced at the American Society of Hematology annual meeting